Dasari Shalini, Choudhary Ankita, Madke Bhushan
Dermatology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND.
Dermatology, B.J. Medical College, Ahmedabad, IND.
Cureus. 2023 Apr 24;15(4):e38037. doi: 10.7759/cureus.38037. eCollection 2023 Apr.
Psoriasis is a multisystem, polygenic, inflammatory condition that typically causes changes in the skin. Although there is a significant genetic component, environmental factors like infections can have a significant impact on triggering the disease. A major part of the pathogenesis of psoriasis is played by the Interleukin (IL) IL23/IL17 axis along with the immune-related cells mainly macrophages and dendritic cells (DCs). Additionally, the role of various cytokines along with the toll-like receptors has also been pointed out in immunopathogenesis. These have been supported by the efficacy of biological therapies including TNF alpha inhibitors and inhibitors of IL17 and IL23. We have summarized the topical as well as systemic therapies for psoriasis including biologics. The article throws light on a few emerging therapeutic options like modulators of sphingosine 1-phosphate receptor 1 and Rho-associated kinase 2 inhibitors.
银屑病是一种多系统、多基因的炎症性疾病，通常会导致皮肤发生变化。虽然存在显著的遗传因素，但感染等环境因素对触发该疾病会产生重大影响。银屑病发病机制的一个主要部分由白细胞介素（IL）IL23/IL17轴以及主要为巨噬细胞和树突状细胞（DCs）的免疫相关细胞发挥作用。此外，各种细胞因子以及Toll样受体在免疫发病机制中的作用也已得到指出。包括肿瘤坏死因子α抑制剂以及IL17和IL23抑制剂在内的生物疗法的疗效也证实了这些作用。我们总结了银屑病的局部和全身治疗方法，包括生物制剂。本文还介绍了一些新兴的治疗选择，如1-磷酸鞘氨醇受体1调节剂和Rho相关激酶2抑制剂。
